Development of technologies for vision impairment

Ramgopal Rao, CEO, 2C Tech Corporation, Inc.

Sixteen million Americans suffer from various ocular diseases, including retinitis pigmentosa, retinal detachment, diabetic retinopathy, and macular degeneration, which ultimately lead to diminished sight and eventually blindness.  The number of such people is growing rapidly as the general population ages. 2C Tech, a Colorado-based ophthalmic medical device company, is working to develop photoactivatable intraocular nanoparticles to convert light to electrical energy for the stimulation of photoreceptors.  Come hear about this technology and the unique challenges of developing technologies for vision impairment.

raoRamgopal Rao, M.B.A., is a serial entrepreneur with 25 years of experience in the ophthalmic pharmaceutical and device industry. Currently he is Chief Executive Officer of 2C Tech Corporation, Inc., an emerging medical device company that is developing a novel nanotechnology application for preservation of vision for patients with macular degeneration and retinitis pigmentosa.  He was previously COO and Director of Vitreoretinal Technologies, Inc., a venture funded ophthalmic pharmaceutical company that developed a drug for diabetic retinopathy.  Mr. Rao co-developed an innovative corneal implant device for presbyopia and licensed the technology to (venture funded) Acufocus, Inc. The company is now in its final stage of US regulatory approval process.  Prior to that, he founded Tomey Technology Inc., that pioneered the corneal topography imaging technology that is now a standard of care in eye care. Mr. Rao was President of Ophthalmic Group at Premier Laser Systems, Inc.; a publicly held company. He also held various executive positions at Biorad Laboratories, Inc.

Time & Location: 123 Snell Library, 3:30pm, February 13